JPWO2022221478A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022221478A5 JPWO2022221478A5 JP2023563172A JP2023563172A JPWO2022221478A5 JP WO2022221478 A5 JPWO2022221478 A5 JP WO2022221478A5 JP 2023563172 A JP2023563172 A JP 2023563172A JP 2023563172 A JP2023563172 A JP 2023563172A JP WO2022221478 A5 JPWO2022221478 A5 JP WO2022221478A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- optionally
- lymphoma
- cells
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 248
- 108091008874 T cell receptors Proteins 0.000 claims description 148
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 138
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 113
- 208000035475 disorder Diseases 0.000 claims description 113
- 102000014914 Carrier Proteins Human genes 0.000 claims description 100
- 108091008324 binding proteins Proteins 0.000 claims description 100
- 238000000034 method Methods 0.000 claims description 79
- 230000003463 hyperproliferative effect Effects 0.000 claims description 69
- 101001000116 Homo sapiens Unconventional myosin-Ig Proteins 0.000 claims description 67
- 102100035824 Unconventional myosin-Ig Human genes 0.000 claims description 67
- 150000007523 nucleic acids Chemical class 0.000 claims description 66
- 230000003211 malignant effect Effects 0.000 claims description 51
- 108010032863 HA-2 antigen Proteins 0.000 claims description 49
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 42
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 40
- 231100000433 cytotoxic Toxicity 0.000 claims description 39
- 230000001472 cytotoxic effect Effects 0.000 claims description 39
- 108020004707 nucleic acids Proteins 0.000 claims description 38
- 102000039446 nucleic acids Human genes 0.000 claims description 38
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 36
- 239000013598 vector Substances 0.000 claims description 35
- 108090000695 Cytokines Proteins 0.000 claims description 29
- 102000004127 Cytokines Human genes 0.000 claims description 29
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 28
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 28
- 206010025323 Lymphomas Diseases 0.000 claims description 25
- 208000032839 leukemia Diseases 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 206010066476 Haematological malignancy Diseases 0.000 claims description 21
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 21
- 239000012636 effector Substances 0.000 claims description 21
- 230000002163 immunogen Effects 0.000 claims description 20
- 108700028369 Alleles Proteins 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 16
- 210000004698 lymphocyte Anatomy 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 206010067959 refractory cytopenia with multilineage dysplasia Diseases 0.000 claims description 16
- 208000013685 acquired idiopathic sideroblastic anemia Diseases 0.000 claims description 15
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 14
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 14
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 14
- 230000006870 function Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 230000004043 responsiveness Effects 0.000 claims description 13
- 238000002965 ELISA Methods 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 12
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 claims description 12
- 241000703392 Tribec virus Species 0.000 claims description 12
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 12
- 238000003127 radioimmunoassay Methods 0.000 claims description 12
- 108700026220 vif Genes Proteins 0.000 claims description 12
- 230000006052 T cell proliferation Effects 0.000 claims description 11
- 208000014951 hematologic disease Diseases 0.000 claims description 11
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 10
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 10
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 10
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 10
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims description 10
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims description 10
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims description 10
- 208000017604 Hodgkin disease Diseases 0.000 claims description 10
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 10
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 10
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 10
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 10
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 10
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 10
- 206010033661 Pancytopenia Diseases 0.000 claims description 10
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 10
- 208000033501 Refractory anemia with excess blasts Diseases 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 10
- 208000024389 cytopenia Diseases 0.000 claims description 10
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 10
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 10
- 208000022769 mixed phenotype acute leukemia Diseases 0.000 claims description 10
- 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 claims description 10
- 206010058314 Dysplasia Diseases 0.000 claims description 9
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 9
- 230000006044 T cell activation Effects 0.000 claims description 9
- 208000005485 Thrombocytosis Diseases 0.000 claims description 9
- 210000004443 dendritic cell Anatomy 0.000 claims description 9
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 9
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 9
- 102000001398 Granzyme Human genes 0.000 claims description 8
- 108060005986 Granzyme Proteins 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 230000002759 chromosomal effect Effects 0.000 claims description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 8
- 210000002865 immune cell Anatomy 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 8
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 6
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 241000288906 Primates Species 0.000 claims description 6
- 208000009527 Refractory anemia Diseases 0.000 claims description 6
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims description 6
- 241000283984 Rodentia Species 0.000 claims description 6
- 238000010171 animal model Methods 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 208000004235 neutropenia Diseases 0.000 claims description 6
- 206010043554 thrombocytopenia Diseases 0.000 claims description 6
- 238000001262 western blot Methods 0.000 claims description 6
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 claims description 5
- 102100033051 40S ribosomal protein S19 Human genes 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims description 5
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 claims description 5
- 208000018240 Bone Marrow Failure disease Diseases 0.000 claims description 5
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 5
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 5
- 206010010099 Combined immunodeficiency Diseases 0.000 claims description 5
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 claims description 5
- 208000000398 DiGeorge Syndrome Diseases 0.000 claims description 5
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 claims description 5
- 201000004939 Fanconi anemia Diseases 0.000 claims description 5
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 5
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 claims description 5
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 5
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims description 5
- 201000003791 MALT lymphoma Diseases 0.000 claims description 5
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 5
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims description 5
- 201000007142 Omenn syndrome Diseases 0.000 claims description 5
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 claims description 5
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims description 5
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims description 5
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims description 5
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 claims description 5
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 5
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 5
- 208000002903 Thalassemia Diseases 0.000 claims description 5
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 claims description 5
- 206010068348 X-linked lymphoproliferative syndrome Diseases 0.000 claims description 5
- 230000022534 cell killing Effects 0.000 claims description 5
- 208000016532 chronic granulomatous disease Diseases 0.000 claims description 5
- 230000003013 cytotoxicity Effects 0.000 claims description 5
- 231100000135 cytotoxicity Toxicity 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 201000003444 follicular lymphoma Diseases 0.000 claims description 5
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 5
- 230000000984 immunochemical effect Effects 0.000 claims description 5
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims description 5
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 5
- 208000019465 refractory cytopenia of childhood Diseases 0.000 claims description 5
- 201000006845 reticulosarcoma Diseases 0.000 claims description 5
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 5
- 208000002491 severe combined immunodeficiency Diseases 0.000 claims description 5
- 208000007056 sickle cell anemia Diseases 0.000 claims description 5
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 4
- 102000005720 Glutathione transferase Human genes 0.000 claims description 4
- 108010070675 Glutathione transferase Proteins 0.000 claims description 4
- 102100037850 Interferon gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 4
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims description 4
- 230000005867 T cell response Effects 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 108010091268 alpha-Macroglobulins Proteins 0.000 claims description 4
- 102000028861 calmodulin binding Human genes 0.000 claims description 4
- 108091000084 calmodulin binding Proteins 0.000 claims description 4
- 210000000349 chromosome Anatomy 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 210000003515 double negative t cell Anatomy 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 210000004700 fetal blood Anatomy 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 229930192851 perforin Natural products 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 210000004986 primary T-cell Anatomy 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 102000034287 fluorescent proteins Human genes 0.000 claims description 3
- 108091006047 fluorescent proteins Proteins 0.000 claims description 3
- 238000003209 gene knockout Methods 0.000 claims description 3
- 238000011469 lymphodepleting chemotherapy Methods 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 102000006395 Globulins Human genes 0.000 claims description 2
- 108010044091 Globulins Proteins 0.000 claims description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 2
- 101800004937 Protein C Proteins 0.000 claims description 2
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims description 2
- 101800001700 Saposin-D Proteins 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 230000001494 anti-thymocyte effect Effects 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000013599 cloning vector Substances 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960000390 fludarabine Drugs 0.000 claims description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 229960000856 protein c Drugs 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 4
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 claims 4
- FTZILAQGHINQQR-UHFFFAOYSA-N alpha-methylpentanal Natural products CCCC(C)C=O FTZILAQGHINQQR-UHFFFAOYSA-N 0.000 claims 4
- 208000003053 chromosome 5q deletion syndrome Diseases 0.000 claims 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010038272 Refractory anaemia with ringed sideroblasts Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163174818P | 2021-04-14 | 2021-04-14 | |
| US63/174,818 | 2021-04-14 | ||
| US202163215760P | 2021-06-28 | 2021-06-28 | |
| US63/215,760 | 2021-06-28 | ||
| US202163288078P | 2021-12-10 | 2021-12-10 | |
| US63/288,078 | 2021-12-10 | ||
| US202263329560P | 2022-04-11 | 2022-04-11 | |
| US63/329,560 | 2022-04-11 | ||
| PCT/US2022/024725 WO2022221478A1 (en) | 2021-04-14 | 2022-04-14 | Binding proteins recognizing ha-2 antigen and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024517618A JP2024517618A (ja) | 2024-04-23 |
| JPWO2022221478A5 true JPWO2022221478A5 (https=) | 2025-04-22 |
| JP2024517618A5 JP2024517618A5 (https=) | 2025-04-22 |
Family
ID=83640691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563172A Pending JP2024517618A (ja) | 2021-04-14 | 2022-04-14 | Ｈａ－２抗原を認識する結合タンパク質及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240197877A1 (https=) |
| EP (1) | EP4322971A4 (https=) |
| JP (1) | JP2024517618A (https=) |
| KR (1) | KR20230170704A (https=) |
| AU (2) | AU2022204581B2 (https=) |
| BR (1) | BR112023021034A2 (https=) |
| CA (1) | CA3215276A1 (https=) |
| IL (1) | IL307429A (https=) |
| MX (1) | MX2023012111A (https=) |
| TW (1) | TW202313670A (https=) |
| WO (1) | WO2022221478A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120530130A (zh) * | 2022-11-29 | 2025-08-22 | 布鲁斯菲尔生物股份有限公司 | 靶向次要组织相容性抗原ha-2的t细胞受体 |
| WO2024148212A2 (en) * | 2023-01-06 | 2024-07-11 | The Trustees Of The University Of Pennsylvania | T cell receptors directed to sox2 protein |
| IL324547A (en) | 2023-05-18 | 2026-01-01 | Clade Therapeutics Inc | Inhibition of natural killer cell cytotoxicity against cellular therapies |
| AU2025202444A1 (en) * | 2024-04-08 | 2025-10-23 | Tscan Therapeutics, Inc. | Use of anti-ha-1 and anti-ha-2 binding proteins for treatment of aml, all, and mds |
| AU2025202443A1 (en) * | 2024-04-08 | 2025-10-23 | Tscan Therapeutics, Inc. | Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318842T1 (de) * | 1995-07-25 | 2006-03-15 | Univ Leiden | Antigenische ha-2 peptide |
| EP1504099A4 (en) * | 2001-12-10 | 2006-05-10 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
| CN110139873A (zh) * | 2016-10-03 | 2019-08-16 | 朱诺治疗学股份有限公司 | Hpv特异性结合分子 |
| MX2019010972A (es) * | 2017-03-15 | 2019-12-02 | Hutchinson Fred Cancer Res | Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos. |
| AU2019249209A1 (en) * | 2018-04-05 | 2020-10-15 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
| EP3670530A1 (en) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
| KR20210149251A (ko) * | 2019-03-08 | 2021-12-08 | 옵시디안 테라퓨틱스, 인크. | 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법 |
| EP3962939A4 (en) * | 2019-05-03 | 2023-05-17 | Gigamune, Inc. | MODIFIED CELLS EXPRESSING ANTITUMOR T-LYMPHOCYTE RECEPTORS AND METHODS OF USING THEM |
-
2022
- 2022-04-14 BR BR112023021034A patent/BR112023021034A2/pt unknown
- 2022-04-14 AU AU2022204581A patent/AU2022204581B2/en active Active
- 2022-04-14 JP JP2023563172A patent/JP2024517618A/ja active Pending
- 2022-04-14 IL IL307429A patent/IL307429A/en unknown
- 2022-04-14 EP EP22788902.9A patent/EP4322971A4/en active Pending
- 2022-04-14 WO PCT/US2022/024725 patent/WO2022221478A1/en not_active Ceased
- 2022-04-14 CA CA3215276A patent/CA3215276A1/en active Pending
- 2022-04-14 MX MX2023012111A patent/MX2023012111A/es unknown
- 2022-04-14 KR KR1020237038120A patent/KR20230170704A/ko active Pending
- 2022-04-14 TW TW111114218A patent/TW202313670A/zh unknown
- 2022-04-14 US US18/286,726 patent/US20240197877A1/en active Pending
-
2023
- 2023-07-13 AU AU2023204645A patent/AU2023204645A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12404317B2 (en) | T cell receptors recognizing MHC class II-restricted MAGE-A3 | |
| US20230203124A1 (en) | Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation | |
| TWI908730B (zh) | 識別p53中之r175h或y220c突變之t細胞受體 | |
| JP2023534808A (ja) | 養子細胞療法のための標的共刺激を提供する受容体 | |
| US20220064257A1 (en) | Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy | |
| Bank et al. | Vδ2+ γδ T lymphocytes are cytotoxic to the MCF 7 breast carcinoma cell line and can be detected among the T cells that infiltrate breast tumors | |
| JPWO2022221478A5 (https=) | ||
| AU2016329542C1 (en) | TCR and uses thereof | |
| JPWO2022099100A5 (https=) | ||
| TWI790162B (zh) | 新穎t細胞受器及使用其之免疫治療 | |
| EP4223782A1 (en) | Novel t cell receptors and immune therapy using the same for the treatment of cancer | |
| US20240360236A1 (en) | Methods for targeted immunotherapy of acute myeloid leukemia (aml) | |
| JPWO2023086480A5 (https=) | ||
| TW202406569A (zh) | 多重ｔ細胞受體組合物、組合療法及其用途 | |
| Plewa | Generation of TGFβR2 (-1) neoantigen-specific human T cell receptors from transgenic mice | |
| JPWO2022221479A5 (https=) | ||
| TW202602496A (zh) | 抗ｈａ－１及抗ｈａ－２結合蛋白用於治療ａｍｌ、ａｌｌ及ｍｄｓ之用途 | |
| EP4326751A1 (en) | Hla class i-restricted t cell receptors against ras with q61k mutation | |
| EP3356396A1 (en) | Tcr and uses thereof |